August 13, 2021
A combination therapy pairing Eisai’s multikinase inhibitor Lenvima (lenvatinib) and MSD’s PD-1 inhibitor Keytruda (pembrolizumab) earned its second approval in the US, for the first-line treatment of advanced renal cell carcinoma (RCC), the companies said on August 11. The greenlight...read more